• Infobird is committed to digitally transforming businesses and whole industries by offering robust customer engagement solutions that embody the crucial aspects of digital transformation
• These aspects, enumerated by Deloitte China, include: digital, analytics, cloud, cybersecurity, and regulatory compliance
• Two retail companies have selected IFBD’s solutions in less than a month
• The collaboration with Zu Li Jian has set up a new path for the digital transformation of retail companies

Evolving customer expectations and business needs have fueled a digital transformation in China, marked by the integration of cloud computing and artificial intelligence (“AI”) into companies’ operations. “To survive in this new world, businesses must learn to observe, think, and operate differently,” reads Deloitte China’s webpage about digital transformation (https://ibn.fm/nPTXa). “Digital transformation, the cross-disciplinary power comprising digital, analytics, cloud, cybersecurity, and regulatory compliance, is about embracing digital disruption and unlocking exponential value.” Interestingly, Infobird Software (NASDAQ: IFBD), a Software-as-a-Service (SaaS) company offering AI-enabled end-to-end customer engagement solutions in China, has packaged the aspects of digital transformation mentioned above, i.e., cloud computing, analytics, cybersecurity, and digital, into its robust proprietary solutions and is using them to help companies around China adapt to the changing times and transform digitally. IFBD’s customer engagement solutions, which integrate the needs of both the customers and the businesses into a single platform, stimulate companies’ market performance and growth and enable them to improve their infrastructure. The platform uses big data and AI to analyze data from multiple channels and subsequently create portraits representing each user, plus their expectations and needs. The platform’s capabilities enable companies to understand their customers more comprehensively and accurately, creating a foundation for precision marketing in e-commerce and physical stores. It is no wonder that IFBD is increasingly witnessing success within the retail industry. A company that leveraged its experience in the finance industry to enter other industries and, as a result, grow its standardized SaaS platform, Infobird has already worked with a leading Chinese multinational technology company specializing in e-commerce and retail. Notably, IFBD appears to be experiencing even more success within this sector. Just recently, Zu Li Jian, the leading shoe company for the elderly in China, selected IFBD’s solutions (https://ibn.fm/WMzM8) less than a month after SaSa Cosmetics (China) Co. Ltd. (https://ibn.fm/8qJXV) entered into a similar cooperative agreement with IFBD. Per both agreements, IFBD’s solutions are intended to digitally improve and optimize the retail companies’ marketing, management, and customer service. The partnership between IFBD and Zu Li Jian, in particular, has set up a new path for the digital transformation of retail companies. This aligns with IFBD’s commitment to continually contribute to the development of more industries and companies. Further, the cooperation promotes the deployment of AI-based SaaS within the retail sector. Infobird, which is keen on capturing the Chinese SaaS market share, is increasingly making strides towards attaining this target, all while digitally transforming companies within the retail industry, as well as other industries. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio
• The company has been issued 19 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world
• Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery
• The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products
• Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021

Lexaria Bioscience (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing. DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future. Lexaria has a collaborative research agreement with the National Research Council (“NRC”), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more. Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products. DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions. DehydraTECH Technology Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect
• Reduces drug administration cost – lower doses mean lower overall drug costs
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine. Market Outlook Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations. John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents. Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations. Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch. Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• HempFusion Wellness Inc. announces it is offering its new EU-compliant products through Boots Ireland
• This marks the company’s official entry into the Irish market in what is a significant step in further venturing into the U.K. and Europe as a whole
• Boots will carry HempFusion’s products in close to 50% of stores in the country
• Following unprecedented circumstances, HempFusion announced a new Chief Financial Officer, Ms. Maria Leal, taking over from Mr. Bruce Valentine
• Ms. Leal will oversee HempFusion’s finance and accounting functions

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) just marked a significant milestone in its European expansion plan. This followed the announcement that it would now be offering its new European Union (“E.U.”) compliant products through its wholly-owned subsidiary, Probulin Probiotics, LLC, via Boots Ireland (https://ibn.fm/iLge8). This entry into the Irish market marks a crucial step in HempFusion Wellness’ ambitious plan to venture into the European market, specifically Ireland, the United Kingdom, and Europe. The move began back in January of 2021 when the initial distribution deal for Ireland was signed, a deal that would see Boots Ireland stock HempFusion’s products in close to 50% of stores in the country. Boots Ireland is a household name in the Irish market. With a history that dates back to 1849, it has become a well-known brand and an integral part of the community (https://ibn.fm/dmABs). The company also serves as part of the Retail Pharmacy International Division of one of the world’s largest purchasers of prescription medication and other health and well-being products. As such, HempFusion’s partnership with Boots Ireland adds substantial value to the brand and plays a critical role in its future expansion plans throughout the rest of Europe and the U.K. Some of the Probulin products stocked in Irish stores will include Women’s Health Probiotic, Probulin Daily Care probiotic, and Total Care Probiotic. As for HempFusion products, Boots will stock 10 mg      USDA Organic Tincture Oil and 20 mg USDA Organic Tincture Oil (https://ibn.fm/6oLwO). HempFusion Wellness, based in Denver, is a world-leading health and wellness CBD company. It prides itself in utilizing the power and potential of whole-food hemp oil that’s been extracted using a proprietary method known to preserve greater numbers of cannabinoids (HempOnePassExtraction(TM)). This organically produced oil serves as the foundation of each of its HempFusion products. Similar care and attention make their way to the development and offerings coming from each of its brands, to include HempFusion, Probulin Probiotics, Biome Research, and H.F. Labs (https://ibn.fm/o35te). Currently, the company’s primary market is the United States, where its products are carried in approximately 4,000 retailers in all 50 states. Consequently, its expansion into Ireland marks a considerable milestone in its move to expand globally, and in Europe, specifically. Additionally, HempFusion announced a new Chief Financial Officer. Ms. Maria Leal, who previously served as the company’s Vice President and Controller, will now take on the position of Interim Chief Financial Officer, taking over from Mr. Bruce Valentine. The latter stepped down effective June 16, 2021, following the unexpected passing of his mother and the duties that arose (https://ibn.fm/CyzmH). Ms. Leal has had a 20-year-long career, serving in various senior positions in financial accounting. Before joining HempFusion in July 2019, she served as Vice President and Corporate Controller at Galvanize Inc., Vice President, Finance at SharpShooter Imaging, and Vice President, Finance North America, and Treasurer at Magic Memories (https://ibn.fm/nIKjP). In a statement from Jason Mitchell, the Cofounder, President, and Chief Executive Officer of HempFusion, HempFusion, through its Board, expressed complete confidence in Ms. Leal’s skills and expertise. The Board noted its trust in Ms. Leal succeeding in overseeing HempFusion’s finance and accounting functions. Mr. Mitchell also recognized Ms. Leal’s role within the company and the value that she has added, particularly to developing and implementing financial planning and accounting functions for the duration she has been part of the company. Ms. Leal holds a CPA and an MBA from Marylhurst University. She also has a Bachelor of Science Degree in Business Administration/Accounting from the California State University- Los Angeles. For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

• PlantX expands its list of elite athletes who partner with the company as brand ambassadors to include Rémy Métailler, one of the world’s most renowned professional mountain bike athletes
• “Rémy’s Picks” has been launched as a personalized web page presenting his curated list of PlantX products
• Métailler, who also follows a mostly plant-based diet, will promote the company’s product offering in Squamish and the Canadian West Coast and across his personal platforms

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) continues to be committed to bringing plant-based living to the broadest audience possible, aiming to demonstrate that this lifestyle can be beneficial even for those that put their bodies under the highest levels of physical stress. The Company adds Rémy Métailler, another high-performing athlete, to its line-up of highly accomplished athletes promoting the PlantX product offering (https://ibn.fm/wJRJa). As more and more elite athletes embrace plant-based nutrition, it becomes increasingly recognized that a plant-based diet may offer considerable benefits in the world of professional sports — from potentially enhancing athletic performance and overall health to helping with injury recovery (https://ibn.fm/n1axJ). Over the recent years, scientists have been studying the role of nutrition in optimizing athletic performance, finding that plant-based diets can help athletes enhance their performance by lowering their weight, creating leaner bodies, and increasing stamina. Today, many elite athletes follow a plant-based diet (https://ibn.fm/h2k4a). Métailler is one of the world’s most renowned professional mountain bike athletes and a planetary health advocate who has been following a mostly plant-based diet. He will be involved in broadening PlantX’s brand exposure in Squamish and the Canadian West Coast, where he currently resides and where PlantX’s flagship store is located. Originally from France, he moved to Squamish, British Columbia —considered The Adventure Capital of Canada — to live his passion for Mountain Biking and skiing. He will also leverage his access to audiences across his personal platforms to help in broadening PlantX’s brand exposure. As part of this partnership, PlantX has launched “Rémy’s Picks”, a personalized web page presenting Métailler’s curated list of PlantX products to U.S. and Canadian e-commerce consumers. Metallier will select his favorite plant-based products from brands such as Oatly, Native Forest, Cadia, and Jeff’s Garden (https://ibn.fm/IcGMt). “I am so excited to partner with PlantX. My diet has been mostly plant-based for several years, and I love trying new recipes,” said PlantX Ambassador, Rémy Métailler. “Having the support of PlantX is a great way to explore new food and lifestyle options and related products that I can share with my community.” “PlantX’s culture is driven by a passion for sports, plant-based wellbeing, and sustainability, and having Rémy’s support further shows how the Company is attracting exciting new partnerships that reflect our values,” said PlantX Founder, Sean Dollinger. “Rémy is a legend in Squamish and in the world of mountain biking. Collaborating with him will help boost our ties with the Squamish community and our brand exposure among other like-minded athletes and their following base.” As a company poised to offer a getaway to plant-based living to consumers across North America, PlantX is committed to offering wholesome products across a broad range of categories for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier, and happier life. In doing so, the Company carefully selects partners with values aligned with its own. As an ardent advocate raising awareness of the climate risks and planetary health Métailler appear to be a perfect partner of PlantX in its quest to promote plant-based living and sustainability efforts. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. To visit the company’s YouTube channel, click here. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Oregon recreational marijuana companies are experiencing the best market conditions in years
• Chalice’s acquisition of Homegrown dispensaries expands company’s retail stores in Oregon from 7 to 12
• CEO says company has ability to significantly increase vertical margin revenue

Business is booming for cannabis companies in Oregon, with a recent Oregon Liquor Control Commission (“OLCC”) study reporting that cannabis production has increased 78% since 2019, while the amount of cannabis sold has skyrocketed by 150% (https://ibn.fm/ta34e). That is welcome news to Chalice Brands (CSE: CHAL) (OTCQB: CHALF), as the company recently announced an acquisition that brought a chain of five Oregon-based retail dispensaries under the Chalice umbrella (https://ibn.fm/1TBUf). “Oregon recreational marijuana companies are experiencing the best market conditions in years, with demand far outpacing supply because of the COVID-19 pandemic and more consumers forgoing the illicit market in favor of legal retailers,” reported a recent MJBizDaily article (https://ibn.fm/K2aYV). The report also noted another key point from the OLCC report: The amount of cannabis harvested in 2020 increased by 37% versus 2019, and the OLCC could issue up to 100 more producer licenses by April. Oregon is the third-largest cannabis market in per capita consumption in the country, reporting $275 annual cannabis spend per capita (https://ibn.fm/xcNBy). The state boasts 16.5 dispensaries per 100,000 residents, offers a stable cultivation and supply chain, and has an optimal climate for growing best-in-class cannabis. Chalice’s acquisition of the Homegrown dispensaries, previously owned by SMS Ventures LLC and located in Portland, Salem and Albany, expands the company’s retail stores from 7 to 12 locations in the state of Oregon. “We have been diligently searching for the appropriate footprint expansion for our retail business in Oregon that represented the right fit and to be in a position to fund the acquisition,” said Chalice Brands president and CEO Jeff Yapp. “Homegrown’s culture aligns perfectly within ours and provides an exceptional geographic compatibility with Chalice and offers an expansion into parts of Oregon in which Chalice does not operate currently. “We have the ability to significantly increase vertical margin revenue through the distribution of our existing edibles and extraction manufacturing as well as our own grow,” Yapp continued. “Homegrown is a well-run retail operation with a very dedicated team at all five stores that we will continue to rely on as we go forward.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• SGTM released Q1-2021 results showing $9,291,931 in revenue, $1,400,720 in gross profit, $41,477,914 in total assets
• QoQ growth includes 16.7% revenue increase, 8.6% gross profit increase
• 2020 was record-breaking year: 794% revenue, 4,817% gross profit growth in Q1 and Q2 compared to all of 2019

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, recently announced Q1-2021 financial results that indicate the company may surpass its record-breaking 2020 financial performance (https://ibn.fm/1Q9cw). The company posted $9,291,931 in revenue, $1,400,720 in gross profit and $41,477,914 in total assets for the three months ending April 3, 2021. Compared to 2020, the results represent an approximate 16.7% increase in revenue, 8.6% increase in gross profit, and 1.4% increase in total assets compared to the three months ended March 31, 2020. “Our continued successful recorded financials each quarter and year-end is all thanks to our team,” said SGTM CEO and Director Tony Raynor. “I’m a firm believer that you are only as strong as your team, and our strong growing financials proves such. This year we are anticipating to continue recording strong financials as we start implementing our strategy for 2021.” SGTM produces environmentally friendly products by diverting natural storm waste from landfills and transforming it into organic garden mulch and playground surfacing material. Through its strategic partners and wholly-owned subsidiaries Mulch Manufacturing Inc. and National Storm Recovery, the company achieves its objectives through tree services, debris hauling and removal, biomass recycling, mulch manufacturing, mulch packaging, next-generation mulch product sales, and the production of specialty cypress lumber. “Getting paid for your feedstock in the mulch business is a recipe for success and great profit margins,” said Raynor (https://ibn.fm/BlbsX). “Storm recovery is a multibillion-dollar business, and we are prepared to help in any cleanup process.” While COVID-19 policies sent the global economy into a tailspin, SGTM experienced stellar financial results in 2020 that included a 794% increase in revenue and a 4,817% increase in gross profit during the first half of the year when compared to all of 2019 combined (https://ibn.fm/v0K7Y). Factors contributing to the company’s impressive performance include a record-breaking hurricane season (https://ibn.fm/HqaVK) and increasing lumber prices (https://ibn.fm/Vo8Cw). The company continues to expand through its strategic partnerships, operational investments, government contracts, and a growing list of commercial clients, including The Kroger Co., Circle K, 7-Eleven, Mendards Inc., Old Castle Lawn & Garden, and more. Based in Jacksonville, Florida, SGTM operates from a 100,000-square-foot warehouse/truck terminal on 26 acres and is managed by a leadership team that leverages over 40 years of next-level experience with mulch manufacturing and tree management. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/LtsUa. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Canadian lawmakers are scheduled to assemble during Q4 to assess past, current, future state of legal cannabis market
• Pac Roots Cannabis has quietly positioned itself as an integrated producer of premium cannabis and hemp
• Pac Roots is generating revenue through a hemp JV, has access to exclusive cultivars, is completing a production facility, has an agreement for more land and recently bought an established cannabis lifestyle brand

The Canadian government has taken a measured approach to legalization of marijuana, but now nearly three years in, advocates will be looking at meaningful progress with regards to regulations to support the industry when a review is expected later this year. As the market has been maturing, Vancouver-based Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) has been steadily building a formidable asset base, including constructing a new production facility, forging a key joint venture and penning an agreement to acquire prime agricultural land as it emerges as a premium provider of cannabis and hemp products with its genetics-focused approach. While the legal cannabis market didn’t get off to the blistering pace some analysts envisioned, it has grown quite briskly and there are signs that the market has reached an inflection point. Deal flow is strong, including Quebec-based Hexo (TSX: HEXO) (NYSE: HEXO) recently agreeing to pay C$925 million for family-owned Redecan, the biggest private Canadian cannabis company by revenue. On June 3, High Tide (NASDAQ: HITI) (TSX.V: HITI) became the first major cannabis retailer to go public on the NASDAQ. Furthermore, the sales scale finally seems to be balancing. In September, it was reported that legal sales in Canada finally exceeded black market marijuana sales for the first time. To help tip the scales in favor of legal sales, Ottawa will need to make some changes – or at least be open to discussions – when it conducts a three-year review. It’s arguable that highly restrictive marketing, production, sales and consumption rules have hamstrung consumer adoption. Pac Roots isn’t looking to get into a pricing war with low-quality suppliers, methodically positioning itself as a premier brand since it came public last year. The company has partnered with Phenome One, one of the largest live genetic libraries in Canada composed of over 350 live cultivars and formed a JV with Rock Creek Farms and Speakeasy Cannabis Club leveraging existing infrastructure, equipment and access to land on a 100-acre hemp project. Despite the coronavirus pandemic and some unseasonable weather conditions, the initial pilot run from the JV resulted in the profitable sale of 105,000 pounds of industrial hemp. The company is wrapping up work on a 20,000-square foot facility in Lake Country, British Columbia. The facility will include about 7,600 square feet of cultivation space supported by a cultivation license expected to be in hand by the fourth quarter of 2021. The plan is to start cycling through the Phenome One cultivars once the license is received. Elsewhere in B.C., Pac Roots completed an agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the Fraser Valley Region, a region famous for its fertile soil and agriculture heritage. The company also recently completed the acquisition of Lords of Grasstown Holdings Ltd., a well-established Cannabis Motorcycle lifestyle brand with a tremendous following and acumen that spawned from the vision of Tyler Hazelwood, founder and director of Lords of Gastown. The popularity of the brand on the West Coast affords Pac Roots an easy entry into vaunted California markets. Interestingly enough, political posturing between Republicans and Democrats about the southern border has illicit drug trafficking in California back in the spotlight, including a massive bust June 8 of over $50 million in marijuana and subsequent bulldozing of 10+ acres of illegal greenhouses that were stealing water for their growing needs. Like Canada, recreational marijuana was made legal in California in 2018. Three years into legalization, both markets are much better understood, as are the tens of billions of dollars legal cannabis contributes to economies. With politicians starting to look ahead to elections in both the U.S. and Canada, it sure will be interesting to see what sort of changes in cannabis just may make it to the campaign trail. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• 11th Annual LD Micro Invitational Conference now available on demand via SRAX’s Sequire investor analytics platform
• Conference featured 25-minute presentations by over 180 microcap companies, including Arch Therapeutics, and GreenPower Motor Company
• Prominent keynote speakers included Jaime Rogozinski, Rishi Khanna and Matt Hulsizer

The 11th Annual LD Micro Invitational Conference is now available on demand via the Sequire SaaS investor analytics platform offered by SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies. The Invitational features 25-minute presentations by over 180 companies on the verge of breaking out in their respective fields, including biotech innovator Arch Therapeutics (https://ibn.fm/Jk4iU) and GreenPower Motor Company, an up-and-coming producer of commercial electric vehicles (https://ibn.fm/weoR9). Also available on demand are exclusive interviews with prominent industry leaders and personalities, including WallStreetBets’ Jaime Rogozinski, Stocktwits’ CEO Rishi Khanna, and Matt Hulsizer, the Co-Founder of PEAK6 (https://ibn.fm/7iTsL). Arch Therapeutics Inc. is a biotechnology company committed to leading the field in stasis and barrier applications that stop bleeding, control leaking, and manage wounds during surgery, trauma and interventional care. The company’s CEO Terrence W. Norchi, MD and CFO Mike Abrams presented the company’s innovative self-assembling barrier platform, describing how the technology can improve surgery outcomes while delivering faster and safer patient care. GreenPower Motor Company –a leading manufacturer and distributor of zero-emission, electric-powered medium and heavy-duty vehicles – was among many environmentally focused companies featured at the conference (https://ibn.fm/RFZLQ). Founded in 2010, the company produces durable, efficient, and affordable battery-electric buses and trucks for various markets that include public transit, schools, vanpools, micro-transit, and shuttle services. The Invitational also included keynotes by notable industry thought leaders and small-cap royalty across corporate media, social media, and capital markets. Among those guests was Jaime Rogozinski, entrepreneur, author, and founder of WallStreetBets –a massive online Reddit community with over 10 million members. He was interviewed by Laurie Segall, CEO of Dot Dot Dot Media and a former CNNMoney technology correspondent, widely known for her in-depth and revealing interviews with prominent entrepreneurs like Mark Zuckerberg, Tim Cook, Jack Dorsey, and Bill Gates. Adding to the theme of social media’s effect on the investment markets was an interview with Rishi Khanna, CEO of Stocktwits –a large investment-focused community with five million registered members. Topping off the lineup was Matt Hulsizer, co-founder of PEAK6 – a billion-dollar investment firm that leverages technology to transform undervalued and underfunded enterprises and help them reach their full potential. Investment interest in microcaps has skyrocketed in recent years, and LD Micro has increasingly played an important role as a media leader. Since its inception in 2006, the company grew from a newsletter into a leading event company and portal that provides exclusive intraday information covering North American stocks with market capitalizations between $50 million and $300 million. SRAX acquired LD Micro in 2020 to accelerate the adoption of Sequire, its SaaS investor analytics platform. Sequire unlocks data analytics that provide critical insights to public companies seeking to track key investors and trading activity. Since its creation in 2019, the platform has grown to over five million investors and traders (https://ibn.fm/ReNQC). To view replays of LD Micro’s Invitational XI Microcap Conference, visit https://ldmicrojune2021.mysequire.com For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Roth’s Healthcare Private Company Forum is currently taking place
• The investor-focused forum will feature a series of corporate fireside chats
• The conference will also play host to three investment panels

Today, Roth Capital Partners (“Roth”) is hosting the Virtual Healthcare Private Company Forum. The event, which is now fully underway, features a number of different healthcare companies drawn from across the biotechnology, pharmaceuticals, and medical technologies verticals. Roth has long been renowned for their experience and ever-growing network within the global healthcare industry, having been involved in more than 530 transactions for its healthcare clients since 2010, with a total transaction value of upwards of $24 billion. With the medical industry and emerging therapeutics sector evolving at a break-neck pace, Roth has sought to host the Healthcare Private Company Forum, providing executive management teams representing established private healthcare companies from across the medical industry an invaluable opportunity to meet and share their respective stories with attendees. “We are excited to host our Virtual Healthcare Private Company Forum for private companies. As the event continues to grow, we are bringing together a broader range of private healthcare companies, from across the US and beyond, to tell their stories,” said James Antonopoulos, Managing Director & Head of Healthcare Investment Banking at Roth. “This event is another example of Roth’s continued leadership in supporting the growth of healthcare companies, including biotechnology, specialty pharmaceuticals, medical devices & diagnostics.” The Roth conference will feature a series of fireside chats, with companies set to address a series of pertinent topics relating to the field of emerging therapeutics. These will include:

• Active Motif: “Enabling Tools and Services for Epigenetics and Gene Regulation Research”
• Aruna Bio: “Utilizing Exosomes to Cross the Blood/Brain”
• Cullgen: “Powering Protein Degradation for Tomorrow’s Medicines”
• Dyve Biosciences: “Breakthrough Drug Delivery Technology Expands Transdermal Therapeutic Options”
• Intensity Therapeutics: “Unprecedented Improvement Upon Intratumoral Injection”
• Reva Medical: “Bioresorbable Polymer Technologies for Vascular Applications”
• Ryvu Therapeutics: “Novel Small Molecule Therapies Addressing High-Value Oncology Indications”

Moreover, the conference will also play host to three discussion panels, featuring leading companies involved within the respective sectors and moderated by Roth research analysts. The panels will touch upon topics such as “Novel Approaches to Tumor Eradication”; “Natural Killer Cell Approaches to Eradicate Tumors”, and the “Next Wave of Psychedelic Drug Developers.” By showcasing some of the industry’s most cutting-edge and privately held companies, Roth Virtual Healthcare Private Company Forum is providing attendees with an invaluable opportunity to discover a number of exciting and innovative companies. For more information about the Roth Virtual Healthcare Private Company Forum, visit www.roth.com/healthcareprivateday

• Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices
• RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain
• Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating

Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. In a recent article, RYAH outlined the history of cannabis clinical trials compared to how they are conducted in 2021. The full report can be found at https://ibn.fm/wwPrP. It’s interesting to note that most cannabis studies have been anti-cannabis, focusing on cannabis-related crime, intoxication/abuse, and use among adolescents until recently. Instead of looking to this plant for its medicinal benefits, the focus has been on its potentially harmful effects. Today, research teams are exploring the use of cannabis to address chronic conditions, especially for pain relief. In the past, studying the plant was complex and controlling dose size and strain profile problematic. In 2019, RYAH began commercializing its smart inhaler solution. Since then, it has created an ecosystem of IoT products, each with three elements: dose-measuring device, medicine-carrying component and a mobile application. The Smart inhaler is the first dry-herb inhaler of its kind where the user can track and control the amount inhaled. This allows for more consistent and predictable results. The connected Health App allows for stat-tracking and presets for both temperatures and dosing, both of which can be adjusted to the user’s needs. The collection of the data provides for efficacy analysis and adjustments to future treatments. RYAH has begun to work with an international oncology clinic in the UK on one of the largest clinical trials of its kind. The company will be studying the safety and efficacy of cannabis and hemp for the treatment of chronic pain. Recently the company successfully shipped 10,000 dry-herb cartridges and QR codes in its initial shipment for the clinic’s pilot run. The complete order includes potentially thousands of RYAH Smart inhalers and millions of proprietary cartridges for the use of this study over the next five years. The future for cannabis study with the addition of dose-measuring devices looks promising. RYAH has found over 400 studies on cannabis that are currently in the recruitment or study phase in the U.S., with more in Canada, the U.K., and Israel. The plant’s many therapeutic benefits are finally being explored, and the potential for creating better treatment plans for patients with various medical conditions is high. Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating. As the perception of cannabis changes in the public eye, so do the opportunities for developing more clinical trials focused on this plant’s therapeutic potential. To learn more about this company, visit  www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH